| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 4, Issue 1 165-170, Copyright © 1998 by American Association for Cancer Research
ARTICLES |
Y Messinger, Y Yanishevski, O Ek, T Zeren, B Waurzyniak, R Gunther, L Chelstrom, M Chandan-Langlie, E Schneider, DE Myers, W Evans and FM Uckun
Wayne Hughes Institute, St. Paul, Minnesota 55113, USA.
B43 (anti-CD19)-genistein immunoconjugate targets genistein, a naturally occurring protein tyrosine kinase-inhibitory isoflavone to the membrane-associated antiapoptotic CD19-LYN complexes and triggers apoptotic cell death. In this preclinical study, the toxicity profiles of B43-genistein as well as unconjugated genistein were evaluated in cynomolgus monkeys. B43-genistein and genistein were administered either as single bolus injections or daily injections for 5-10 consecutive days via the i.v. route to monkeys. Neither genistein nor B43-genistein was toxic to cynomolgus monkeys, and no test article-related histopathological lesions were found in any of the two genistein-treated or five B43-genistein-treated cynomolgus monkeys. B43-genistein showed a favorable pharmacokinetics in monkeys, with a plasma half-life of 10-23 h. Plasma samples from B43-genistein-treated monkeys elicited potent and CD19 antigenspecific antileukemic activity against human CD19+ leukemia cells in vitro. To our knowledge, this is the first preclinical toxicity and pharmacokinetic study of a tyrosine kinase inhibitor-containing immunoconjugate in nonhuman primates.
This article has been cited by other articles:
|
|
 |
|
  R. Malaviya, C.-L. Chen, C. Navara, R. Malaviya, X.-P. Liu, M. Keenan, B. Waurzyniak, and F. M. Uckun Treatment of Allergic Asthma by Targeting Janus Kinase 3-Dependent Leukotriene Synthesis in Mast Cells with 4-(3',5'-Dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97) J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 912 - 926. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. M. Uckun, Y. Messinger, C.-L. Chen, K. O'Neill, D. E. Myers, F. Goldman, C. Hurvitz, J. T. Casper, and A. Levine Treatment of Therapy-Refractory B-Lineage Acute Lymphoblastic Leukemia with an Apoptosis-inducing CD19-directed Tyrosine Kinase Inhibitor Clin. Cancer Res., December 1, 1999; 5(12): 3906 - 3913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Uckun, O. Ek, X.-P. Liu, and C.-L. Chen In Vivo Toxicity and Pharmacokinetic Features of the Janus Kinase 3 Inhibitor WHI-P131 [4-(4'Hydroxyphenyl)-Amino-6,7-Dimethoxyquinazoline] Clin. Cancer Res., October 1, 1999; 5(10): 2954 - 2962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Sudbeck, X.-P. Liu, R. K. Narla, S. Mahajan, S. Ghosh, C. Mao, and F. M. Uckun Structure-based Design of Specific Inhibitors of Janus Kinase 3 as Apoptosis-inducing Antileukemic Agents Clin. Cancer Res., June 1, 1999; 5(6): 1569 - 1582. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
